Navigate BioPharma Services Unveils New Assay for Precise Measurement of Radioligand Therapies
Navigate BioPharma Services, Inc. has introduced a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors.
Navigate BioPharma Services | 01/06/2024 | By Aishwarya | 167
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy